Oncolytics Biotech (ONCY) News Today → Healthcare Takes A Big Step Forward With The Help Of AI (From The Bull Report) (Ad) Free ONCY Stock Alerts $1.06 +0.02 (+1.92%) (As of 09:57 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineClosing Bell: Oncolytics Bio up on Friday (ONC)theglobeandmail.com - April 21 at 5:51 PMBiotech Breakthroughs Spearhead Fight Against Rising Breast Cancer Casestheglobeandmail.com - April 13 at 12:42 AMUSA News Group: Biotech Innovations Paving the Way in Breast Cancer Fightfinanznachrichten.de - April 11 at 2:15 PMOncolytics seeking FDA meeting to discuss registration-enabling studymsn.com - April 11 at 2:15 PMOncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDAprnewswire.com - April 11 at 7:00 AMOncolytics Biotech (NASDAQ:ONCY) Now Covered by Analysts at Raymond Jamesmarketbeat.com - April 4 at 2:58 PMOncolytics Biotech (NASDAQ:ONCY) Trading Down 1.9%marketbeat.com - March 21 at 12:58 AMUSA News Group: Biotech's Role in Addressing the Pancreatic Cancer Emergencyfinanznachrichten.de - March 14 at 9:24 AMBuy Rating Affirmed for Oncolytics Biotech Amidst Promising Pipeline and Advancements in Cancer Treatment Trialsmarkets.businessinsider.com - March 11 at 7:59 AMOncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 10 at 10:18 AMBuy Rating Affirmed on Oncolytics Biotech Amid Progress and Strategic Clinical Trialsmarkets.businessinsider.com - March 8 at 8:46 PMOncolytics Biotech Inc.: Oncolytics Biotech Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlightsfinanznachrichten.de - March 8 at 10:45 AMOncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlightsprnewswire.com - March 7 at 4:01 PMOncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCANprnewswire.com - March 5 at 7:00 AMOncolytics Biotech (ONCY) Scheduled to Post Quarterly Earnings on Thursdaymarketbeat.com - February 28 at 7:33 AMOncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conferenceprnewswire.com - February 28 at 7:00 AMHere's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situationfinance.yahoo.com - February 15 at 3:44 PMOncolytics Biotech Incbaystreet.ca - February 15 at 10:44 AMOncolytics Biotech Inc.: Oncolytics Biotech Initiates Enrollment Expansion of GOBLET Anal Cancer Cohortfinanznachrichten.de - February 14 at 1:27 PMOncolytics Biotech® Inc.: Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohortfinanznachrichten.de - February 14 at 8:27 AMOncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohortfinance.yahoo.com - February 14 at 8:27 AMOncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohortprnewswire.com - February 14 at 7:00 AMOncolytics Biotech (NASDAQ:ONCY) Trading 2.9% Higher marketbeat.com - February 10 at 12:48 AMOutlook stock rallies on private placement, FDA study agreementmsn.com - January 23 at 11:32 AMOncolytics Biotech® Inc.: Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directorsfinanznachrichten.de - January 9 at 7:50 AMOncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directorsfinance.yahoo.com - January 9 at 7:50 AMOncolytics Biotech® Inc.: Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024finanznachrichten.de - January 4 at 10:36 AMOncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024finance.yahoo.com - January 4 at 10:36 AMOncolytics Biotech® and SOLTI Present Positive Translational Data at SABCSfinance.yahoo.com - December 15 at 10:02 AMOncolytics Biotech: Numerous Early Readouts, But Dwindling Reservesseekingalpha.com - December 11 at 8:35 AMOptimistic Outlook on Oncolytics Biotech Backed by Promising Pelareorep Trial Data and Strong Valuationmarkets.businessinsider.com - December 8 at 8:18 AMImproving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatmentfinance.yahoo.com - November 29 at 1:42 PMPositive Outlook on Oncolytics Biotech: Insights into Clinical Trials and Future Plansmarkets.businessinsider.com - November 10 at 6:49 PMOncolytics Announced Positive Interim Results From Phase 1/2 GOBLET Study In Anal Cancermarkets.businessinsider.com - November 9 at 9:57 AMOncolytics Biotech Inc ONCYmorningstar.com - November 9 at 12:06 AMPositive Outlook for Oncolytics Biotech: Upcoming Clinical Trials, Business Developments, and Solid Financial Position Drive Buy Ratingmarkets.businessinsider.com - November 6 at 11:44 PMOncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 5 at 3:26 PMBuy Rating for Oncolytics Biotech Backed by Positive GOBLET Study Results in Pancreatic and Metastatic Colorectal Cancer Treatmentsmarkets.businessinsider.com - October 25 at 12:11 PMOncolytics Biotech® Inc.: Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Studyfinanznachrichten.de - October 23 at 9:15 AMOncolytics Biotech® Inc.: Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMOfinanznachrichten.de - October 23 at 9:15 AMOncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Studyfinance.yahoo.com - October 23 at 9:15 AMOncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMOfinance.yahoo.com - October 23 at 9:15 AMPositive Trial Results and Future Plans Prompt ‘Buy’ Rating for Oncolytics Biotech, Inc.markets.businessinsider.com - October 21 at 2:04 PMOncolytics Biotech® To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023finance.yahoo.com - October 16 at 7:54 AMUSA News Group: Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatmentfinanznachrichten.de - October 11 at 10:07 AMBreakthroughs in Pancreatic Cancer Treatment: How FDA Designations are Changing the Gamebaystreet.ca - October 11 at 10:07 AMPancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Casesbenzinga.com - September 26 at 12:06 PMTHE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTSfinance.yahoo.com - September 26 at 7:06 AMPioneering Cancer Treatments Show Promising Progress Despite Fiscal Challengesbaystreet.ca - September 20 at 10:42 AMAdvancements in Pancreatic Cancer Treatment: Biotech Innovations and Rising Optimismbaystreet.ca - September 19 at 5:32 PM Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter. Email Address One trade. One ticker. One week. (Ad)Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? Well, then you should click here to see this free training. ONCY Media Mentions By Week ONCY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ONCY News Sentiment▼0.000.46▲Average Medical News Sentiment ONCY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ONCY Articles This Week▼11▲ONCY Articles Average Week Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Affimed News Today Eton Pharmaceuticals News Today BioXcel Therapeutics News Today Chimerix News Today PMV Pharmaceuticals News Today Hookipa Pharma News Today YS Biopharma News Today Spero Therapeutics News Today InflaRx News Today Clearside Biomedical News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ONCY) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
